Although the increased use of androgen deprivation therapy for prostate cancer might be improving survival, a recent large retrospective cohort study that analysed hospital medical record data indicates that long therapy duration is associated with an increased risk of Alzheimer's disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Development of a machine learning model to predict mild cognitive impairment using natural language processing in the absence of screening
BMC Medical Informatics and Decision Making Open Access 12 May 2022
-
Inverse Correlation Between Alzheimer’s Disease and Cancer: Short Overview
Molecular Neurobiology Open Access 14 September 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fuller, S. J., Tan, R. S. & Martins, R. N. Androgens in the etiology of Alzheimer's disease in aging men and possible therapeutic interventions. J. Alzheimers Dis. 12, 129–142 (2007).
Gandy, S. et al. Chemical andropause and amyloid-beta peptide. JAMA 285, 2195–2196 (2001).
Lv, W. et al. Low testosterone level and risk of Alzheimer's disease in the elderly men: a systematic review and meta-analysis. Mol. Neurobiol. http://dx.doi.org/10.1007/s12035-015-9315-y (2015).
Nead, K. T. et al. Androgen deprivation therapy and future Alzheimer's disease risk. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2015.63.6266 (2015).
Frain, L. et al. A reduced risk of Alzheimer's disease is associated with the majority of cancers in a national cohort of veterans. Alzheimers Dement. 9 (Suppl.), 617 (2013).
Wahjoepramono, E. J. et al. The effects of testosterone supplementation on cognitive functioning in older men. CNS Neurol. Disord. Drug Targets http://dx.doi.org/10.2174/1871527315666151110125704 (2015).
Hormone (androgen deprivation) therapy for prostate cancer. Cancer.org [online], (2001).
Verdile, G. et al. The impact of luteinizing hormone and testosterone on beta amyloid (Aβ) accumulation: animal and human clinical studies. Horm. Behav. 76, 81–90 (2015).
Jack, C. R. Jr et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 81, 1732–1740 (2013).
Hershman, D. L. et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol. http://dx.doi.org/10.1001/jamaoncol.2015.4655 (2015).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Martins, R., Gandy, S. Increased dementia risk following androgen deprivation therapy?. Nat Rev Urol 13, 188–189 (2016). https://doi.org/10.1038/nrurol.2016.34
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.34
This article is cited by
-
Development of a machine learning model to predict mild cognitive impairment using natural language processing in the absence of screening
BMC Medical Informatics and Decision Making (2022)
-
Inverse Correlation Between Alzheimer’s Disease and Cancer: Short Overview
Molecular Neurobiology (2021)
